Private Capital Group LLC boosted its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 1,904.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,889 shares of the pharmaceutical company’s stock after acquiring an additional 3,695 shares during the quarter. Private Capital Group LLC’s holdings in GlaxoSmithKline were worth $154,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in GSK. First Trust Advisors LP boosted its holdings in GlaxoSmithKline by 26.1% during the 4th quarter. First Trust Advisors LP now owns 619,519 shares of the pharmaceutical company’s stock valued at $21,974,000 after acquiring an additional 128,188 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of GlaxoSmithKline by 132.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 717,841 shares of the pharmaceutical company’s stock valued at $25,462,000 after buying an additional 408,441 shares during the period. Financial Counselors Inc. boosted its stake in shares of GlaxoSmithKline by 10.9% in the 4th quarter. Financial Counselors Inc. now owns 199,083 shares of the pharmaceutical company’s stock valued at $7,061,000 after buying an additional 19,572 shares during the period. Stockman Wealth Management Inc. boosted its stake in shares of GlaxoSmithKline by 7.0% in the 4th quarter. Stockman Wealth Management Inc. now owns 78,742 shares of the pharmaceutical company’s stock valued at $2,793,000 after buying an additional 5,185 shares during the period. Finally, BancorpSouth Bank purchased a new position in shares of GlaxoSmithKline in the 4th quarter valued at about $324,000. Institutional investors own 11.07% of the company’s stock.
GlaxoSmithKline opened at $40.31 on Friday, MarketBeat reports. The company has a current ratio of 0.61, a quick ratio of 0.40 and a debt-to-equity ratio of 3.90. GlaxoSmithKline plc has a 1-year low of $34.52 and a 1-year high of $43.31. The company has a market capitalization of $98.11 billion, a P/E ratio of 14.00, a price-to-earnings-growth ratio of 2.27 and a beta of 0.83.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.70 by ($0.02). The business had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $10.26 billion. GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. equities analysts anticipate that GlaxoSmithKline plc will post 2.79 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, July 12th. Shareholders of record on Friday, May 11th will be given a dividend of $0.5298 per share. The ex-dividend date is Thursday, May 10th. This represents a $2.12 dividend on an annualized basis and a yield of 5.26%. GlaxoSmithKline’s payout ratio is 72.92%.
Several equities research analysts have recently weighed in on the company. ValuEngine lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Friday, May 4th. DZ Bank reissued a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, June 14th. Zacks Investment Research lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Friday, June 8th. Finally, Deutsche Bank reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Wednesday, March 28th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $40.21.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.